Drawing for CHARIOTEER

USPTO serial 79066733

CHARIOTEER

Reviewed by CopyMark Law Group

Reg. 3722653Status 706Registered
Filing date
Status date
Registration date
Dec 8, 2009
Examiner
LEE, DEBRA ANN
Law office
GENERIC WEB UPDATE

What this means

This trademark is registered with the USPTO. Monitoring new filings can help you catch lookalike marks early.

Need help with CHARIOTEER?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Antipyretyc, analgesic and anti-inflammatory active pharmaceutical ingredient, namely, naproxen, naproxen sodium, naproxen celecoxib, nimesulide, aceclofenac, sulindac, ibuprofen, fenoprofen, ketoprofen, celecoxib, nimesulide, aceclofenac; anti-inflammatory active pharmaceutical ingredient, namely, naproxen nitroxyalkylesters; antipyretic and analgesic active pharmaceutical ingredient, namely, aspirin, acetaminophen, propyphenazone; antipyretic and analgesic, antithrombotic active pharmaceutical ingredient, namely, indomethacin; analgesic active pharmaceutical ingredient, namely, eptazocine, ketorolac tromethamine; antipyretic, analgesic active pharmaceutical ingredient, namely, propyphenazone; anti-inflammatory and anti-virus active pharmaceutical ingredient, namely, amantadine hydrochloride; treating rheumatoid arthritis active pharmaceutical ingredient, namely, flurbiprofen, meloxicam, phenylbutazone; anti-platelet aggregation active pharmaceutical ingredient, namely, clopidogrel hydrogen sulfate; anti-platelet drugs active pharmaceutical ingredient, namely, prasugrel; anti-cancer active pharmaceutical ingredient, namely, topotecan hydrochloride, ifosfamide, mesna, irinotecan, camptothecin, 7-ethyl-10-hydrol-camptothecin, docetaxel; treating iodine deficiency active pharmaceutical ingredient, namely, iodine; anti-goitre expectoration and active pharmaceutical ingredient, namely, potassium iodide; treating supraventricular arrhythmia, typical angina and variant angina active pharmaceutical ingredient, namely, diltiazem; anti-hepatitis B virus active pharmaceutical ingredient, namely, adefovir dipivoxil, lamivudine, telbivudine, clevudine; anti-urogenital system disease active pharmaceutical ingredient, namely, phenazopyridine hydrochloride; anti-virus active pharmaceutical ingredient, namely, acyclovir, acyclovir sodium, penciclovir, zidovudine, ganciclovir, ganciclovir sodium, famciclovir, valaciclovir hydrochloride, valganciclovir hydrochloride, ribavirin, 6-deoxyacyclovir, polyinosinic polycytidylic acid, interferons, adenine, farmivisen, docosanol, zanamvir, oseltamivir, indinavir, ritonavir, nelfinavir, delavirdine, efavirenz, ainprenavir, lopinavir, cidofovir, imiquimod, didanosine, foscarnet sodium, penciclovir sodium, stavudine, abacavir, tenofovir disoproxil, emdtricitabine, brivudine, amprenavir, rimantadine; expectorant active pharmaceutical ingredient, namely, fudosteine, carbocisteine; anti-hypertension active pharmaceutical ingredient, namely, valsartan, losartan, irbesartan, tasosartan, candesartan, telmisartan, eprosartan, olmesartan; anxiolytic active pharmaceutical ingredient, namely, brofoxine; treating coronary heart disease active pharmaceutical ingredient, namely, dipyridamole; immunosuppressive active pharmaceutical ingredient, namely, tacrolimus; immunosuppressive agents active pharmaceutical ingredient, namely, sirolimus; treating cardiac and cerebrovascular disease active pharmaceutical ingredient, namely, nicergoline; treating coronary heart disease active pharmaceutical ingredient, namely, isosorbide mononitrate; anti-obesity active pharmaceutical ingredient, namely, orlistat; antipsychotic active pharmaceutical ingredient, namely, perazine maleate, carisoprodol; anti-leprosy disease active pharmaceutical ingredient, namely, thalidomide; anti-vitamin deficiency active pharmaceutical ingredient, namely, folic acid, dexpanthenol; anti-megaloblastic anemia active pharmaceutical ingredient, namely, calcium levofolinate; antithrombotic active pharmaceutical ingredient, namely, ticlopidine hydrochloride; anti-rejection active pharmaceutical ingredient, namely, rapamycin, mizoribine, mycophenolic acid, mycophenolate mofetil, mycophenolate sodium, clarithromycin, daptomycin, mupirocin, ertapenem, doripenem, biapenem, meropenem, imipenem, faropenem, aztreonam, benflumetol, mupirocin, caspofungin; treating diabetes mellitus active pharmaceutical ingredient, namely, metformin, voglibose; antioxidant, treatment heart disease and anti-hypertension active pharmaceutical ingredient, namely, coenzyme Q10; treating brain edema and glaucoma active pharmaceutical ingredient, namely, isosorbide; anti-aids active pharmaceutical ingredient, namely, nevirapineACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jul 30, 2019NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Jul 30, 201971AGREGISTERED-SEC.71 ACCEPTED—
Jul 26, 2019TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jul 26, 2019ES71TEAS SECTION 71 RECEIVED—
Dec 28, 2018RNWLINTERNATIONAL REGISTRATION RENEWED—
Dec 8, 2018REM4COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED—
Jan 15, 2015NA71NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED—
Jan 15, 201571AGREGISTERED-SEC.71 ACCEPTED—
Jan 15, 2015APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Dec 11, 2014ES71TEAS SECTION 71 RECEIVED—
Dec 11, 2014TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jan 30, 2013FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 1, 2010FICSFINAL DISPOSITION NOTICE SENT TO IB—
Apr 1, 2010FIMPFINAL DISPOSITION PROCESSED—
Mar 9, 2010FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Dec 8, 2009R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 22, 2009PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 2, 2009NPUBNOTICE OF PUBLICATION—
Aug 18, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 18, 2009ALIEASSIGNED TO LIE—
Aug 11, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jul 20, 2009TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jul 15, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jul 15, 2009TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
May 22, 2009RFNTREFUSAL PROCESSED BY IB—
Apr 27, 2009RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Apr 27, 2009RFRRREFUSAL PROCESSED BY MPU—
Apr 26, 2009RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Apr 25, 2009CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Apr 21, 2009MAFRAPPLICATION FILING RECEIPT MAILED—
Apr 17, 2009DOCKASSIGNED TO EXAMINER—
Apr 17, 2009NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 16, 2009REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance